CD40LG and infection: The proportion of S-IgM seropositive participants gradually decreased from 51% at baseline to 24% on D28PB, surged to 57% at six months, suggesting possible breakthrough infections, and then sharply fell to 6% by 12 months (Supplementary Figure 1F).